BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34468397)

  • 1. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study.
    Köhler A; Sarkis AL; Heinrich DA; Müller L; Handgriff L; Deniz S; Schneider H; Künzel H; Ladurner R; Reincke M; Adolf C
    Eur J Endocrinol; 2021 Oct; 185(5):663-672. PubMed ID: 34468397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy.
    Adolf C; Köhler A; Franke A; Lang K; Riester A; Löw A; Heinrich DA; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Arlt W; Reincke M
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4543-4552. PubMed ID: 30113683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nadir Aldosterone Levels After Confirmatory Tests Are Correlated With Left Ventricular Hypertrophy in Primary Aldosteronism.
    Ohno Y; Sone M; Inagaki N; Kawashima A; Takeda Y; Yoneda T; Kurihara I; Itoh H; Tsuiki M; Ichijo T; Katabami T; Wada N; Sakamoto R; Ogawa Y; Yoshimoto T; Yamada T; Kawashima J; Matsuda Y; Kobayashi H; Kamemura K; Yamamoto K; Otsuki M; Okamura S; Izawa S; Okamoto R; Tamura K; Tanabe A; Naruse M;
    Hypertension; 2020 Jun; 75(6):1475-1482. PubMed ID: 32248705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
    Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
    High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism.
    Pan CT; Wu XM; Tsai CH; Chang YY; Chen ZW; Chang CC; Lee BC; Liao CW; Chen YL; Lin LC; Chang YR; Hung CS; Lin YH
    Front Endocrinol (Lausanne); 2021; 12():646097. PubMed ID: 33953695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone.
    Künzel HE; Apostolopoulou K; Pallauf A; Gerum S; Merkle K; Schulz S; Fischer E; Brand V; Bidlingmaier M; Endres S; Beuschlein F; Reincke M
    J Psychiatr Res; 2012 Dec; 46(12):1650-4. PubMed ID: 23017810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism.
    Hung CS; Ho YL; Chang YY; Wu VC; Wu XM; Lee JK; Chueh SC; Lin YH; Changh YS; Yang SY; Hu YH; Sui MJ; Chen MF; Wu KD
    ScientificWorldJournal; 2013; 2013():294594. PubMed ID: 24459427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
    Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
    Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.
    Rossi GP; Cesari M; Cuspidi C; Maiolino G; Cicala MV; Bisogni V; Mantero F; Pessina AC
    Hypertension; 2013 Jul; 62(1):62-9. PubMed ID: 23648698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy.
    Lin YH; Huang KH; Lee JK; Wang SM; Yen RF; Wu VC; Chung SD; Liu KL; Chueh SC; Lin LY; Ho YL; Chen MF; Wu KD;
    J Renin Angiotensin Aldosterone Syst; 2011 Mar; 12(1):48-53. PubMed ID: 20719880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Left ventricular myocardial structure and function in patients with primary aldosteronism].
    Arabidze GG; Chikhladze NM; Sergakova LM; Iarovaia EB
    Ter Arkh; 1999; 71(9):13-9. PubMed ID: 10553618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
    Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary Salt Intake Is a Determinant of Cardiac Changes After Treatment of Primary Aldosteronism: A Prospective Study.
    Catena C; Colussi G; Novello M; Verheyen ND; Bertin N; Pilz S; Tomaschitz A; Sechi LA
    Hypertension; 2016 Jul; 68(1):204-12. PubMed ID: 27245179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.
    Pintus G; Seccia TM; Amar L; Azizi M; Riester A; Reincke M; Widimský J; Naruse M; Kocjan T; Negro A; Kline G; Tanabe A; Satoh F; Rump LC; Vonend O; Fuller PJ; Yang J; Chee NYN; Magill SB; Shafigullina Z; Quinkler M; Oliveras A; Lee BC; Chang CC; Wu VC; Krátká Z; Battistel M; Bagordo D; Caroccia B; Ceolotto G; Rossitto G; Rossi GP
    Hypertension; 2024 Jun; 81(6):1391-1399. PubMed ID: 38525605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
    Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
    J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
    Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
    Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
    Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism.
    Lin YH; Wu XM; Lee HH; Lee JK; Liu YC; Chang HW; Lin CY; Wu VC; Chueh SC; Lin LC; Lo MT; Ho YL; Wu KD;
    J Hypertens; 2012 Aug; 30(8):1606-13. PubMed ID: 22688266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study.
    Chen ZW; Huang KC; Lee JK; Lin LC; Chen CW; Chang YY; Liao CW; Wu VC; Hung CS; Lin YH;
    J Hypertens; 2018 Feb; 36(2):353-360. PubMed ID: 28902663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.